KR1 Plc - Interim Report for the Half Year Ended 30 June 2025 PR Newswire LONDON, United Kingdom, September 30 30 September 2025 KR1 plc (the "Company) Interim Report for ...

Eddie Morris, Josep Serrano Torres, and Jen Breeze of Deloitte compare transfer pricing controversies in the pharmaceutical and automotive sectors, highlighting how DEMPE functions, regulation, and in ...

Coherus Oncology's Loqtorzi has resumed growth in earnest, with Q2 2025 net revenues of $10M. Click here to find out why CHRS ...

Q4 2025 Earnings Call Transcript September 23, 2025 Operator: Greetings. Welcome to the Aytu BioPharma, Inc. report for ...

Royalty revenue contribution expected to begin as early as 2030 Initial partner targets include derisked MoAs that are ...

Raise Up Massachusetts is campaigning for a shift in state spending and tax policies to generate $1.6 billion in revenue to ...

As global tax regimes increasingly prioritize transparent reporting, responsible governance, and sustainable development, the convergence of Environmental, Social, and Governance (ESG) principles, ...

IRS rules research and development services U.S. entities provide to their foreign parent principal company may be ...

Merck has raised its dividend for 14 consecutive years and at an average pace of nearly 7% over the last five years. The ...

Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout ...

Updated Outlook BGC reaffirmed its previously stated outlook ranges for revenue and pre-tax Adjusted Earnings for the third quarter of 2025. The Company's outlook was contained in BGC's financial ...

Last patient last visit (LPLV) milestone in AFFIRM-1 Phase 3 trial of BNC-210 in social anxiety disorder (SAD) achieved; topline readout anticipated in early Q4 2025 Cash runway extended through fisca ...